Leukemias, lymphomas, and other hematologic cancers:
Indications for SARCLISA:
In combination with pomalidomide and dexamethasone, for the treatment of multiple myeloma in adults who have received ≥2 prior therapies including lenalidomide and a proteasome inhibitor.
Premedicate with dexamethasone (oral or IV), acetaminophen (oral), H2 antagonists, diphenhydramine (oral or IV) 15–60mins prior to infusion. Give as an IV infusion. 10mg/kg on Days 1, 8, 15, and 22 for Cycle 1; then 10mg/kg on Days 1 and 15 for Cycle 2 onward until disease progression or unacceptable toxicity. Each cycle consists of a 28-day period. Infusion rates: see full labeling.
Should be administered by a healthcare professional with access to emergency equipment and medical support. Monitor for infusion-related reactions. Interrupt if Grade 1 or 2 infusion reactions occur; if symptoms improve, restart at half the initial infusion rate; monitor closely. Permanently discontinue if ≥Grade 3 infusion-related reaction occurs. Risk for neutropenia; monitor for infections. Obtain CBCs during therapy; if Grade 4 neutropenia occurs, delay dose until neutrophil count recovery to ≥1.0×109/L. Monitor for second primary malignancies development as per IMWG guidelines. Elderly. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for ≥5 months after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended.
CD38-directed monoclonal antibody.
May interfere with serological testing (eg, indirect antiglobulin [Coombs] test, antibody detection, antihuman globulin crossmatches), serum protein electrophoresis and immunofixation assays leading to false (+) results.
Neutropenia, upper respiratory tract infection, infusion-related reactions, pneumonia, diarrhea; other lab abnormalities (eg, anemia, lymphopenia, thrombocytopenia), second primary malignancies.